急性白血病免疫治疗的临床经验与前景

发布时间：2018-02-23 21:14

本文关键词： 急性白血病免疫治疗临床结果经验前景　出处：《中国肿瘤临床》2017年06期 　论文类型：期刊论文

【摘要】：近年来,急性白血病(acute leukemia,AL)的免疫治疗已获得一些突破性进展。本文旨在总结AL免疫治疗的结果和经验,如抗CD19抗原嵌合受体基因工程修饰T细胞、抗CD3/19双特异抗体治疗,使部分难治复发急性B淋巴细胞白血病(refractory relapse acute B lymphocytic leukemia,r/r B-ALL)获得完全缓解(complete remission,CR)。本研究团队采用化疗联合自体细胞因子诱导的杀伤细胞、自然杀伤细胞,明显提高第一次CR期中低危险性AL的长期无病生存率(disease-free survival,DFS)。其他多种免疫治疗方法的研究也逐步开展,如针对其他靶点的抗原嵌合受体基因工程修饰T细胞、T细胞抗原受体基因修饰的T细胞,其他靶点的双特异性抗体、针对免疫细胞周期卡控点的抗体或药物等。多种免疫治疗及方法的联合有望提高AL的治愈率及生存质量,从而减少采用对生存质量影响更大的异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,Allo-HCT)的治疗方法。
[Abstract]:In recent years , some breakthrough advances have been made in immunotherapy of acute leukemia ( AL ) . The aim of this paper is to summarize the results and experiences of AL immunotherapy , such as anti - CD 19 antigen chimeric receptor gene engineering modified T cell and anti - CD3 / 19 double - specific antibody treatment , so that partial refractory relapse acute B - lymphoblastic leukemia ( r / r B - ALL ) is completely remission ( CR ) . The study team used chemotherapy combined with autologous cytokine - induced killer cells and natural killer cells to significantly increase the long - term disease - free survival ( DFS ) of low - risk AL in the first CR period . The research of many other immunotherapy methods is gradually carried out , such as modified T cell , T cell antigen receptor gene modified T cell , double - specific antibody of other target sites , antibody or drug for immune cell cycle clamping point , etc . for other target antigen chimeric receptor gene engineering . The combination of various immunotherapy and methods is expected to improve the cure rate and quality of life of AL , thus reducing the treatment method of allogeneic hematopoietic stem cell transplantation ( Allo - HCT ) which has greater influence on survival quality .

【作者单位】：河北燕达陆道培医院血液科;
【分类号】：R733.71

【参考文献】